Decitabine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DECITABINE |
|---|---|
| Type | Drug |
| Aliases | DacogenInqovi (oral, with cedazuridine)Децитабін |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Drug Facts
| Class | Hypomethylating agent (cytidine analog) |
|---|---|
| Mechanism | Deoxyribonucleoside analog of cytidine; incorporated into DNA, irreversibly inhibits DNA methyltransferases at low doses, cytotoxic at higher doses. Alternative to azacitidine for MDS-HR and AML; oral formulation Inqovi (decitabine+cedazuridine) approved for MDS. |
| Typical dosing | IV 20 mg/m²/day × 5 days every 28-day cycle (most common). 10-day schedule (20 mg/m² days 1-10) historically used in elderly AML but largely replaced by ven+aza. Inqovi: 35 mg decitabine + 100 mg cedazuridine PO once daily days 1-5 q28d. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Functionally equivalent to azacitidine for HMA-naive MDS-HR; selection often based on local availability and reimbursement. Some retrospective data favor decitabine for TP53-mutated AML/MDS but no head-to-head RCT. Oral Inqovi simplifies MDS administration.
Used By
No reverse references found in the YAML corpus.